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Short Report 
Desipramine Subsensitizes Nicotinic 
Mechanism Involved in Regulating 
Core Temperature 
Abstract. Desipramine HCI, IO mg/kg i.p. 
twice daily, produced subsensitivity to the 
hypothermic effects of nicotine, I mg/kg, 
after I and 2 weeks of treatment in male 
Sprague-Dawley rats, Phenelzine sulfate, 
fluoxetine HCI, and bright artificial light 
produced the same effect. The capacity of 
three chemically distinct classes of anti- 
depressants and bright artificial light (a 
treatment for seasonal depression) to pro- 
duce this result suggests that effects on 
nicotinic mechanisms may be involved in the 
mechanism of action of these treatments. 
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The effects of antidepressants on nicotinic 
mechanisms have received minimal attention. 
Shaker et al. (1981) and Schofield et al. 
(198 I) presented evidence that tricyclic 
antidepressants bind to sites on the ionic 
channel of the nicotinic receptor (nAchR). 
We studied the effects of fluoxetine, phenel- 
zinc, amitriptyline, lithium, and bright 
artificial light on a nicotinic mechanism 
involved in the regulation of core tempera- 
ture in rats (Dilsaver and Hariharan, in 
press). We now report the effects of 
desipramine HCI (DM I) on this mechanism. 
Methods 
This report includes three experiments 
involving adult male Sprague-Dawley rats. 
Experiment I involves the measurement of 
change in core temperature in response to 
nicotine (base), I mg/ kg i.p., before and after 
I and 2 weeks of treatment with DMI, IO 
mg/kg i.p., at 9 a.m. and 5 p.m. in I2 rats 
with a mean weight of 319.2 (SD 46.1) g. 
Experiment 2 was a study of the effects of 
DMI on the disposition of nicotine in two 
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samples of IO rats each. The first group was 
treated with DMI, IO mg/kg i.p., at 9 a.m. 
and 5 p.m. for I4 days. The mean weight of 
this sample was 236.5 (SD 32.9) g. The 
second sample received saline injections, I 
mg/kg i.p., at 9 a.m. and 5 p.m. for I4 days. 
The mean weight of this sample was 288.0 
(SD 13.3) g. Experiment 3 was a control 
experiment in which eight animals with a 
mean weight of 303 (SD 29.7) g were 
challenged with nicotine (base), I mg/ kg i.p., 
every 7 days for 3 weeks. The mean hypo- 
thermic response to nicotine was measured 
after the first and fourth injections. The 
objective was to demonstrate that multiple 
injections of nicotine at the dose used in 
Experiment I do not produce subsensitivity 
to nicotine. 
Measurement of Core Body Tempera- 
ture. Telemetric thermosensors (Mini-Mitter 
Corp., Sun River, OR) were implanted into 
the peritoneal cavity. Dilsaver et al. (in press) 
established the validity of this method. 
Nicotine Challenge. Nicotine challenges 
were conducted at IO a.m. Challenge I oc- 
curred the day before treatment started. 
Challenges 2 and 3 occurred 20 hours after 
the 14th and 28th doses of DMI. Tempera- 
ture was measured immediately before and 
every IO min after the injection of nicotine 
(base), I mg/kg .i.p.. for ! 19 z+. S!zc!ins 
temperature for a given challenge is defined 
as the core temperature immediately before 
the injection of nicotine. 
Assay of Plasma Levels of Nicotine and 
Metabolites. Plasma levels of nicotine and 
cotinine were determined by a high per- 
formance liquid chromatography (H PLC) 
method using a UV detector (262 nm) and 
2-phenylimidazole as an internal standard. 
0165-178 I /88/$03.50 0 1988 Elsevier Scientific Publishers Ireland Ltd. 
106 
The mobile phase is a citrate-phosphate 
buffer mixture (0.03 M each) with a final pH 
of 5.0, and containing 7% acetonitrile and 2 
mM solidum hepatanesulphonate. A C-18 
Shandon column (Keystone Co., State 
College, PA) with a length of I50 mm and a 
diameter of 2 mm is used. The analytes are 
extracted from alkalinized plasma using 
methylene chloride. After separation, the 
organic solvent is evaporated using nitrogen 
gas. The residue is reconstituted with 50~1 of 
mobile phase, and 20 PI is injected into the 
column. The sensitivity of the assay is I 
ng/ ml for nicotine and 2 ng/ ml for cotinine. 
The method is linear from 0 to 600 ng/ml for 
both analytes. The precision of the assay is 
5% (coefficient of variation) (n = 30) for both 
substances (Hariharan et al., 1987). 
Pharmaceuticals. DMI HCI and nicotine 
(base) were purchased from Sigma Chemical 
Company (St. Louis, MO). Doses of DMI 
and nicotine refer to the salt and base forms, 
respectively. Both agents were administered 
i.p. on an mg/ kg basis. 
Experimental Design-Study 1. This 
study was divided into two phases. In Phase 
I, the thermosensors were implanted into I2 
animals, which were allowed a minimum of 5 
days to recover. During Phase 2, the hypo- 
thermic response to normal saline, I mg/ kg 
i.p., was measured. This provides a baseline 
taking into account the effects of handling 
and “placebo” injection. The thermic 
response to nicotine, I mg/kg i.p., was 
subsequently measured. The animals then 
received twice-daily injections (at 9 a.m. and 
5 p.m.) of DMI, IO mg/ kg i.p. Twenty hours 
after the 14th and 28th doses of DMI, the 
animals were rechallenged with nicotine. 
Experimental Design-Study 2. Ten ani- 
mals were treated with DMI for I4 days. The 
animals were then injected with nicotine, I 
mg/ kg i.p., between 0930h and I230h. They 
were anesthetized with diethyl ether, and 30 
min after the injection of nicotine, blood was 
drawn by cardiac puncture for the determina- 
tion of plasma nicotine and cotinine levels. 
These levels were compared to those in the IO 
animals treated with saline. 
Experimental Design-Study 3. Thermo- 
sensors were implanted into eight rats, which 
were allowed 5 days to recover before experi- 
mentation began. The sample then received 
nicotine, I mg/ kg i.p., every 7 days for 21 
days. The thermic response to this drug was 
measured every IO min for I20 min following 
the first and fourth injections of nicotine. 
Statistical Analysis. Data from Experi- 
ments I and 3 were derived by calculating the 
mean thermic response across weeks for each 
rat. Mean temperature change between the 
challenges for each animal was then used to 
determine the significance of the mean 
change in temperature for the sample using 
Student’s paired I test. The significance of the 
differences in the mean plasma nicotine and 
cotinine levels in Experiment 2 was deter- 
mined using Student’s two-sampled t test. 
Measures of variance refer to the SD. 
Results 
Experiment 1. Mean core temperature of 
this sample before the first experimental 
manipulation was 37.1 f 0.45”C. Table I 
summarizes the results of this experiment. 
The thermic response to nicotine between I 
and 2 weeks of treatment did not differ 
(I = 0.88, df= I I; p > 0.35). 
Table 1. Exaeriment 1 
Mean thermic 
Mean thermic response to 
response to nicotine after 
nicotine DMI treatment 
-1.43+0.62% After 1 week: -0.56f0.76W 
After 2 weeks: -0.80f0.73W 
DMI = desipramine. 
1.t=3.04,df=11,~<0.05. 
2.t=3.56,df=11,~<0.005. 
Experiment 2. The mean nicotine levels in 
the experimental and control groups were 
318.2 (SD 32.9) and 220.3 (SD 48.5) ng/ml, 
respectively (1 = 5.57, df= 18, p < 0.00003). 
The mean cotinine levels were 87.0 (SD 35.0) 
and 232. I (SD 81.9) ng/ml, respectively 
(t = 5.22, df = 18, p < 0.000006). Thus, 
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treatment with DMI was associated with 
highly elevated levels of plasma nicotine. The 
elevated levels of cotinine in the control 
sample relative to the experimental group 
suggest that DMI retarded the metabolism of 
nicotine. 
Experiment 3. The mean hypothermic 
response to nicotine, I mg/ kg i.p., was -I .37 
(SD 0.23)“C when the sample was first 
challenged, and -1.32 (SD 0.2O)“C at the time 
of the fourth challenge (f = 0.67, df = 7, 
p > 0.50). Thus, multiple injections of 
nicotine did not produce subsensitivity to 
subsequent challenges. 
Discussion 
Treatment with DMI produced subsensitivity 
to nicotine. This effect was not due to a 
pharmacokinetic factor. Indeed, the DMI 
sample had a level of plasma nicotine that 
was 44% higher than that of the saline sample 
(p < 0.00003). Further, the saline sample had 
a much lower mean ratio of plasma nicotine 
to cotinine, I.0 (SD 0.09) as opposed to 4.0 
(SD 0.39) in the DMI group @ < O.OOOOOl). 
We can conclude that the development of 
subsensitivity to nicotine is probably due 
to a pharmacodynamic effect of treatment 
with DMI. 
Bright artificial light (Dilsaver and 
Majchrzak, I988), fluoxetine (Dilsaver and 
Davidson, 1987), and phenelzine (Dilsaver 
and Hariharan, in press) also produce 
subsensitivity to the hypothermic effect of 
nicotine. Thus, drugs from three chemical 
classes and a nonpharmacological treatment 
for depression all blunt the hypothermic 
response to nicotine. There are two 
exceptions. Treatment for I or 2 weeks with 
amitriptyline (D&aver et al., 1988) and 
lithium (Dilsaver and Hariharan, in press) 
produces supersensitivity to nicotine. We 
suggest that the essential point is not that 
there are exceptions to the results presented 
here but that all treatments for depression 
assessed affect a nicotinic mechanism in- 
volved in the regulation of core temperature. 
Nicotine promotes the release of nor- 
epinephrine in the hypothalamus (Westfall, 
1973) and dopamine within the mesolimbic 
and nigrostriatal tracts (Andersonn et al., 
1981). Should an antidepressant enhance 
aminergic activity, nicotinic mechanisms 
with which it interacts might become subsen- 
sitive. Alternatively, drugs supersensitizing 
nicotinic mechanisms, such as amitriptyline, 
might activate aminergic pathways. It is 
conceivable that both drugs which supersensi- 
tize and those which subsensitize nicotinic 
mechanisms have antidepressant properties. 
The significance of the phenomenon reported 
here is yet to be determined. However, the 
array of antidepressant treatments producing 
it suggests potential importance. 
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